F-star Therapeutics cashes in on new Takeda deal


F-star in Cambridge – an invoX company – has entered into a second licence agreement with Takeda, the Japanese multinational pharma business, for a novel next-generation immuno-oncology bispecific antibody.

Based at Babraham Research Campus, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialise a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.

Takeda will be responsible for all research, development and commercialisation activities.

F-star will receive an undisclosed upfront licence fee and is eligible to receive potential future development and commercialisation milestone payments, plus royalties on annual net sales.

This is the second option that Takeda has exercised under an evaluation and licence agreement with F-star struck in July 2021. F-star and Takeda entered into a licence agreement for a different bispecific antibody in July 2022.

Neil Brewis, F-star’s CEO, said: “This second licence agreement with Takeda provides further validation of the enormous potential of F-star’s mAb2 TM platform to produce multiple next-generation bispecific antibody therapeutics.

“We look forward to our continued partnership with Takeda who share our vision of developing pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives.”

Kathy Seidl, head of the Oncology Drug Discovery Unit at Takeda, added: “Takeda is committed to developing novel therapies that harness the innate immune system to fight cancer.

“This second licence agreement with F-star allows us to apply the mAb2 TM platform to generate novel bispecific antibodies leveraging innate immune mechanisms to eliminate tumour cells creating value for the patients we serve.”

Article sourced from Business Weekly